Physician profile
David B Gamble
NPI 1033423249
$835,567.57
in general payments reported to CMS, 2019-2025
42 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119K · 2022: $187K · 2023: $167K · 2024: $194K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400K · Travel and Lodging: $94K · Food and Beverage: $21K · Consulting Fee: $5,779 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,881 · Honoraria: $3,750 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $399,769.01 |
| Travel and Lodging | $94,238.58 |
| Food and Beverage | $21,430.19 |
| Consulting Fee | $5,778.67 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,880.63 |
| Honoraria | $3,750.00 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $430,231.20 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $131,252.18 | 2021-2025 | Korlym |
| Novo Nordisk INC | $82,518.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59,211.09 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $46,500.72 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45,407.54 | 2021-2025 | |
| Abbott Laboratories | $35,717.61 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $933.56 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $713.45 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $475.28 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $366.99 | 2021-2025 | Tepezza, Repatha, Repatha |
| Radius Health, INC. | $292.42 | 2021-2025 | Tymlos |
| Antares Pharma, INC. | $258.00 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Merck Sharp & Dohme LLC | $239.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $213.09 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $206.58 | 2021-2022 | |
| Medtronic, INC. | $84.38 | 2023-2025 | Minimed 780g |
| Vistapharm, INC. | $61.07 | 2021 | |
| Chiesi USA, INC. | $60.94 | 2024 | Juxtapid, Mycapssa |
| Neurocrine Biosciences, INC. | $59.43 | 2024 | |
| Boston Scientific Corporation | $58.89 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Recordati_rare_diseases_inc. | $56.08 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $54.24 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $46.53 | 2022-2023 | Strensiq |
| Kyowa Kirin, INC. | $43.36 | 2023-2024 | Crysvita |
| Horizon Therapeutics Plc | $41.92 | 2021-2023 | Tepezza |
| Eusa Pharma (US) LLC | $41.52 | 2022 | |
| Astellas Pharma US INC | $38.34 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $38.23 | 2023-2025 | |
| Ascendis Pharma Endocrinology INC | $37.71 | 2023-2025 | Yorvipath |
| Regeneron Healthcare Solutions, INC. | $36.47 | 2024 | Evkeeza |
| Amarin Pharma, INC. | $36.20 | 2021 | |
| Grt US Holding, INC. | $34.76 | 2022 | |
| Beta Bionics, INC. | $31.11 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Arbor Pharmaceuticals, INC. | $29.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.44 | 2023-2024 | |
| Amryt Pharma Holdings Ltd | $26.83 | 2023 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $25.81 | 2024 | Baqsimi |
| Amneal Pharmaceuticals LLC | $16.64 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $14.82 | 2022 | |
| Madrigal Pharmaceuticals | $14.40 | 2025 | Rezdiffra |
| Zealand Pharma US, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.